

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**GUIDANCE EXECUTIVE (GE)**

**Consideration of consultation responses on review proposal**

**Review of TA177; Alitretinoin for the treatment of severe chronic hand eczema**

This guidance was issued August 2009 with a review date of August 2012.

**Background**

At the GE meeting of 31 July 2012 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

<b>Proposal put to consultees:</b>	The guidance should be transferred to the 'static guidance list'.
<b>Rationale for selecting this proposal</b>	No new evidence has emerged since the publication of TA177 and there are no changes in the marketing authorisation or price. There are very few ongoing trials and the results of these are not expected to change the recommendations.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

<b>Recommendation post consultation:</b>	The guidance should be transferred to the 'static guidance list'.
--	---

<b>Respondent</b>	<b>Response to proposal</b>	<b>Details</b>	<b>Comment from Technology Appraisals</b>
GlaxoSmithKline	Agree	<p>We agree with NICE’s proposal to move TA 177 to the static list due to “No new evidence has emerged since the publication of TA177 and there are no changes in the marketing authorisation or price. There are very few ongoing trials and the results of these are not expected to change the recommendations.”</p> <p>We are responding in both the capacity as manufacturer of azathioprine and alitretinoin, which we recently acquired as part of our purchase of Basilea.</p>	Comment noted.
British Association of Dermatologists	Agree	<p>On behalf of the Therapy &amp; Guidelines sub-committee of the British Association of Dermatologists I would like to confirm our agreement with NICE’s proposal to move the guidance to the static list due to insufficient new evidence to warrant an update.</p>	Comment noted.
Royal College of Nursing	No comment	<p>This is just to let you know that the feedback received from nurses working in this area of health suggests that there are no additional comments to submit on the proposal to review the above guidance.</p>	Comment noted.
Royal College of Physicians	Agree	<p>The RCP wishes to endorse the comment submitted by the British Association of Dermatologists.</p>	Comment noted.

**No response received from:**

Patient/carer groups

- Action Against Allergy
- Afiya Trust
- Allergy UK
- Black Health Agency
- Changing faces
- Counsel and Care
- Equalities National Council
- Let's Face It
- Muslim Council of Britain
- Muslim Health Network
- National Eczema Society
- Skin Care Campaign
- South Asian Health Foundation
- Specialised Healthcare Alliance

Professional groups

- British Association for Services to the Elderly
- British Contact Dermatitis Society
- British Dermatological Nursing Group
- British Geriatrics Society
- British Skin Foundation
- Primary Care Dermatology Society
- Royal College of General Practitioners
- Royal College of Pathologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- United Kingdom Clinical Pharmacy Association

General

- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Commissioning Support Appraisals Service
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Public Health Wales NHS Trust
- Scottish Medicines Consortium

Comparator manufacturer(s)

- Actavis UK (azathioprine)
- Arrow Generics (azathioprine)
- Aspen Holdings Global (azathioprine)
- Dexcel-Pharma (ciclosporin)
- Mylan UK (azathioprine, ciclosporin)
- Novartis Pharmaceuticals (ciclosporin)
- Sandoz (azathioprine)
- Sinclair Pharmaceuticals (azathioprine)
- Teva UK (azathioprine)

<p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Cheshire, Warrington and Wirral PCT Cluster</li> <li>• Department of Health</li> <li>• Tees PCT Cluster</li> <li>• Welsh Government</li> </ul>	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Epidermo-Epidemiology Society</li> <li>• Cochrane Skin Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> <li>• Skin Research Centre</li> <li>• Skin Treatment &amp; Research Trust</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>
--	---

**GE paper sign-off:** Elisabeth George, Associate Director – Technology Appraisals Programme

**Contributors to this paper:**

Technical Lead: Grace Jennings

Technical Adviser: Kay Nolan

Project Manager: Andrew Kenyon

18 September 2012